FDA supports tighter restrictions on hydrocodone
WASHINGTON — The Food and Drug Administration is recommending tighter restrictions on prescription medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the United States.
In a major policy shift, the agency said in an online notice on Thursday that hydrocodone-containing drugs should be subject to the same restrictions as other narcotic drugs such as oxycodone and morphine.
More than a decade has passed since the Drug Enforcement Agency asked the FDA to reclassify hydrocodone so that it would be subject to the same restrictions as other opioid drugs. The FDA did not issue a formal announcement about its decision, which has long been sought by many patient advocates, doctors and lawmakers.
In early December, the FDA says it will formally request that hydrocodone be classified as a Schedule II drug, limiting who can write a prescription and how many times it can be refilled.
Show commenting policy
TribLive commenting policy
- More rain worsens flooding in Texas
- Oregon proposal would outlaw sneak photos up women’s skirts
- IRS says hackers stole tax info from 100,000
- Texas man charged with helping friend’s bid to join ISIS
- Doctors, hospitals get more time to convert to electronic health records
- Biden reassures Iraq: U.S. backs your forces in fight against Islamic State
- Ex-coal boss Blankenship wants July trial delayed to January
- Patriot Act deal looks unlikely
- Shootings, slayings surge during Memorial Day weekend in Chicago, Baltimore
- Airman kills 1 in North Dakota store